Erectile dysfunction: Symptom or disease?

Journal of Endocrinological Investigation

Volumn 27, Issue 1, 2004, Pages 80-95

  Foresta, Carlo ^a   Caretta, N ^a   Aversa, A ^b   Bettocchi, C ^c   Corona, G ^d   Mariani, S ^e   Rossato, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular disease; Diabetes; Diagnostic approach; Erectile dysfunction; Hypertension; NPTRM; Penile color doppler ultrasound

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; BARBITURIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTYROPHENONE DERIVATIVE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CLONIDINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; GLUCOSE; HYDRALAZINE; LAMOTRIGINE; LOOP DIURETIC AGENT; METHYLDOPA; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NITRATE; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PIMOZIDE; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ANAMNESIS; ANGIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAVERNOSOGRAPHY; CLINICAL PRACTICE; COLOR ULTRASOUND FLOWMETRY; COMORBIDITY; DATA ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC TEST; DIET RESTRICTION; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; ERGOMETRY; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; MALE; MEDICAL SPECIALIST; NEUROLOGIC EXAMINATION; NEUROPATHY; ORAL GLUCOSE TOLERANCE TEST; PATIENT SELECTION; PENIS ERECTION; PENIS NOCTURNAL TUMESCENCE; PHYSICAL EXAMINATION; PHYSICIAN; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SATISFACTION; SEXUAL INTERCOURSE; SYMPTOMATOLOGY; WELLBEING;

EID: 1542316218     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350917     Document Type: Review

References (120)

1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993, 270: 83-90.
2. Wagner G, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Imp Res 2000, Suppl 4: S144-6.
3. Spera G, Mariani S, Spera E, Pili M. La disfunzione erettile come sintomo di patologie internistiche: nuove frontiere terapeutiche. Atti del 103° Congresso Nazionale della Società Italiana di Medicina Interna. Milano, 19-22 novembre 2002. Ann Ital Med Int. 2002, 17: 33S-42S.
4. DeWire DM. Evaluation and treatment of erectile dysfunction. Am Fam Physician. 1995, 53: 2101-07.
5. Deutsch S, Sherman L. Previously unrecognized diabetes mellitus in sexually impotent men. JAMA 1980, 244: 2430-2.
6. Sairam K, McNicholas TA. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU 2001, 88: 68-71.
7. Soo Woong K. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urol. 2001, 58: 441-5.
8. Kawanishi Y, Sogou T. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunction patients. Int J Impot Res 2001, 13: 100-3.
9. Billups K, Friedrich S. Assessment of fasting lipid panels and Doppler ultrasound testing in men presenting with erectile dysfunction and no other medical problems. 95th Annual Meeting of the American Urological Association. 2000, Atlanta, GA. Abstract 655.
10. Aversa A, Isidori AM, Lenzi A, Spera G, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf), 2003, 58: 632-8.
11. Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi J. Guidelines on Erectile Dysfunction. E Urol 2002, 41: 1-5.
12. Canadian Urological Association Guidelines Committee. Erectile dysfunction practice guidelines. Can J Urol 2002, 9: 1583-87.
13. Furlow WL. Prevalence of impotence in the United States. Med Aspects Hum Sex 1985, 19: 13-16.
14. Kinsey AC, Martin CE. Sexual Behaviour in Human Males. Philadelphia, Saunders, 1948.
15. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983, 249: 1736-42.
16. Diokno AC, Herzog AR. Sexual function in the elderly. Arch Intern Med 1990, 150: 197-200.
17. Feldman HA, Goldstein I, et al. Impotence and its medical and psychological correlates: results of the Massachusetts Male Ageing Study. J Urol 1994, 151: 54-61.
18. Parazzini F, Menchini Fabris F, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000, 37: 43-49.
19. Vallancien G, Emberton M, Harving N, Jeroen R, van Moorselaar A. Sexual dysfunction in 1,274 european men suffering from lower urinary tract symptoms. J Urol 2003, 169: 2257-61.
20. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey". Int J Impot Res 2000, 12: 305-11.
21. Wei M, Macera CA, Davis DR. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994, 140: 930-7.
22. Tengs TO, Osgood ND. The link between smoking and impotence. Two decades of evidence. Prev Med 2001, 32: 447-52.
23. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980, 18: 279-83.
24. Rubin A. Impotence and diabetes mellitus. JAMA 1958; 168: 496.
25. Brunner GA, Pieber TR, Schattenberg S, et al. Erectile dysfunction in patients with type I diabetes mellitus. Wien Med Wochenschr 1995, 145: 584-6.
26. Klein R, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996, 19: 135-41.
27. Johannes CB, Feldman HA, Araujo AB, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000, 163: 460-3.
28. Fedele D, Coscelli C, Forti G, et al. Incidence of erectile dysfunction in italian men with diabetes. J Urol 2001,166: 1368-71.
29. Fugl-Meyer AR, Fugl-Meyer KS, Lundberg PO. Sexual rehabilitation. In: Frommelt P. Grotzbach eds. Neurorehabilitation. Oxford: Blackwell. 1999, 370-88.
30. Lundberg PO, Ertekin C, Ghezzi A, Swash M, Vodusek D. Neurosexology. Eur J Neurol 2001, 8 (Suppl. 3): 2-24.
31. Lue TF. Erectile dysfunction. N Engl J Med 2000, 342: 1802-13.
32. Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997, 158: 1768-9.
33. Johri AM, Heaton JP, Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 2001, 13: 176-82.
34. Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001, 21: 676-83.
35. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001, 165: 430-35.
36. Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachusetts Male Aging Study. Soc Sci Med 2000, 51: 771-78.
37. Marumo K, Murai M. Aging and erectile dysfunction: the role of aging and concomitant chronic illness. Int J Urol 2001, 8:S50-57.
38. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995, 56: 137-41.
39. Aversa A, Rocchietti-March M, Caprio M, et al. Pharmacology of male sexual dysfunction. Minerva Endocrinol 1998, 23: 17-25.
40. Bradford JMW. Treatment of sexual offenders with cyproterone acetate. In: Sitsen JMA ed. Handbook of sexology. Amsterdam: Elsevier 1988, 526-36.
41. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000, 164: 1189-91.
42. De Rose AF, Carmignani G, Corbu C, et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002, 68: 95-8.
43. Donahue JL, Lowenthal DT. Androgens, anabolic-androgenic steroids and inhibitors. Am J Ther 2000, 7: 365-73.
44. Epstein RJ, Allen RC, Lunde MW. Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. Ann Ophthalmol 1987, 19: 48-50.
45. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002, 63 (Suppl 59): 13-6.
46. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002, 4: 202-10.
47. Grimm RH, Grandis GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of mild hypertension Study. Hypertension 1997, 29: 8-17.
48. Husain AM, Carwile ST, Miller PP, Radtke RA. Improved sexual function in three man taking lamotrigine for epilepsy. South Med J 2000, 93: 335-6.
49. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999, 12: 271-5.
50. Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999, 18: 5-24.
51. Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002, 18: 103-7.
52. Lambert MV. Seizures, hormones and sexuality. Seizure 2001, 10:319-40.
53. Langford HG, Rockhold RW, Wassertheil-Smoller S, Oberman A, Davis BR, Blaufox MD. Effect of weight loss on thiazide produced erectile problems in men. Trans Am Clin Climatol Assoc 1989, 101: 190-4.
54. Listerri JL, Lozano Vidal A et al. CM. Sexual dysfunction in hypetensive patients treated with losartan. Am J Med Sci 2001, 321: 336-41.
55. Mari D. Andrologic problems and internal pathology in the elderly. Arch Ital Urol Androl 1993, 65: 507-10.
56. Mikhailidis DP, Khan MA, Milionis HJ, Morgan RJ. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000, 16 (Suppl 1): 31-6.
57. Muller SC, El-Damanhoury H, Ruth J, Lue TF. Hypertension and impotence. Eur Urol 1991, 19:29-34.
58. Pillay VK. Some side effects of alfa-methyldopa. S Afr Med J 1976, 50: 625-6.
59. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999, 21: 241-42.
60. Segraves RT. Sexual side effects of psychiatric drugs. Int J Psychiatry Med 1988, 18: 243-52.
61. Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician 1991, 44: 2075-82.
62. Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995, 45: 498-52.
63. Speckens AM. Discrimination between psychogenic and organic erectile dysfunction. J Psychosom Res 1993, 37: 135.
64. Tiefer L, Schuetz-Mueller D. Psycological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am 1995, 22: 767-73.
65. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridge 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999, 11: 319-26.
66. Akerman MD, D'Attilio JP. Sexual Dysfunction: a Neuro-Medical Approach. Armoni, NY: Futura Publishing Company, Inc. 1994, 229-44.
67. Petrone L, Mannucci E, Corona G, et al. Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003 15: 210-20.
68. Kandeel FR, Koussa V, Swerdloff R. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation and treatment. Endocr Rev 2001, 22: 342-88.
69. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med 2000, 109: 3S-12S.
70. The process of care consensus panel. Position paper: the process of care model for evaluation and treatment of erectile dysfunction. Int J Imp Res 1999, 11: 59-74.
71. Breda G, Breda G, Xausa D, et al. Nomogram for penile biothesiometry. Eur Urol 1991, 20: 67-9.
72. Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 2001, 28: 279-88.
73. Vermeulen A, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666-72.
74. Johri AM, Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 2001, 13: 176-82.
75. Carani C, Marrama P. Prolactin and testosterone: their role in male sexual function. Int J Androl 1996, 19: 48-54.
76. Bradley WE, Timm GW, Gallagher JM, Johnson BK. New method for continuous measurement of nocturnal penile tumescence and rigidity. Urology 1985, 26: 4-6.
77. Levine L, Lenting EL. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol Clin North Am 1995, 22: 775-88.
78. Eardley I, Sethia K. Erectile Dysfunction - Current Investigation and management. London: Mosby-Wolfe. 1998.
79. Schiavi RC. The role of sleep laboratory in the evaluation of male erectile dysfunction. Mt Sinai J Med 1994, 61: 161-5.
80. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989, 321: 1648-59.
81. Mueller SC, Schild HH. Comparison of selective internal iliac pharmaco-angiography, penile brachial index and duplex sonography with pulsed Doppler analysis for the evaluation of vasculogenic (arteriogenic) impotence. J Urol 1990, 143: 928-32.
82. Aitchison M, Aitchison J, Carter R. Is the penile brachial index a reproducible and useful measurement? Br J Urol 1990, 66: 202-4.
83. Linet OI, Ogrinc FG. Efficacy and safety of intracavemousal alprostadil in men with erectile dysfunction. New Eng J Med 1996, 334: 873-7.
84. Belgrano E, Savoca G. Disfunzione erettiva: Le linee guida della Consensus di Trieste. Milano: Ariete Salute Editore, 2001.
85. Aversa A, Rocchietti-March M, Isidori A, Fabbri A. Anxiety induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach. Int J Androl 1996, 19: 307-13.
86. Pescatori E, Hatzichristou DG, Namburi S, Goldstein I. A positive intracavernous injection test implies a normal veno-occlusive but not necessarily normal arterial function: a haemodynamic study. J Urol 1994, 151: 1209-16.
87. Aversa A, Isidori AM, Cerilli M, Frajese V, Fabbri A. Penile pharmacotesting in diagnosing male erectile dysfunction: evidence for a lack of accuracy and specificity. Int J Androl 2002, 25: 6-10.
88. Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high resolution ultrasonography and pulsed doppler spectrum analysis. Radiology 1985, 155: 777-81.
89. Cormio L, Bettocchi C, Ricapito V, Zizzi V, Traficante A, Selvaggi FP. Resistance index as a prognostic factor for prolonged erection after penile dynamic colour Doppler ultrasonography. Eur Urol 1998, 33: 94-7.
90. Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000, 53: 517-22.
91. Mancini M, Bartolini M, Maggi M, Innocenti P, Forti G. The presence of arterial anatomical variations can affect the results of duplex sonographic evaluation of penile vessels in impotent patients. J Urol 1996, 155: 1919-23.
92. Cormio L, Nisen H, Ruutu M, Selvaggi FP. Etilefrine in the prevention of prolonged erection after diagnostic pharmacological stimulation. Ann Chir Gynaecol 1996, 85: 247-50.
93. Slob AK, Cornelissen S, Dohle GR, Gijs L, van der Werfften Bosch JJ. The limited practical value of color Doppler sonography in the differential diagnosis of men with erectile dysfunction. Int J Impot Res 2002, 14: 201-3.
94. Montorsi F, Guazzoni G, Bergamaschi F, et al. Vascular abnormalities in Peyronie's disease: the role of color doppler sonography. J Urol 1994, 151: 373-5.
95. Delcour C, Struyven J. Techniques for performing cavernosometry and cavernosography. Cardiovasc Intervent Radiol 1988, 11: 211-7.
96. Montague DK, Lakin MM. False diagnoses of venous leak impotence. J Urol 1992, 148:148-9.
97. Petrou S, Lewis RW. Management of corporeal veno-occlusive dysfunction. Urol Int 1992, 49: 48-55.
98. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995, 75: 191-236.
99. Giuliano FA, Jardin A. Neural control of penile erection. Urol Clin North Am 1995, 138: 747-66.
100. Padma-Nathan H. Neurologic evaluation of erectile dysfunction. Urol Clin North Am 1988, 15: 77-80.
101. Lin JT, Bradley WE. Penile neuropathy in insulin-dependent diabetes mellitus. J Urol 1985, 133: 213-5.
102. Espino P. Neurogenic impotence: diagnostic value of nerve conduction studies, bulbocavernosus reflex and heart rate variability. Electromyogr Clin Neurophysiol 1994, 34: 373-6.
103. Bemelmans BL, Debruyne FM. Penile sensory disorders in erectile dysfunction: results of a comprehensive neuro-urophysiological diagnostic evaluation in 123 patients. J Urol 1991, 146: 742-77.
104. Nikiforidis G, Barbalias G. Reduced variance of latencies in pudendal evoked potentials after normalization for body height. Neurourol Urodyn 1995, 14:239-51.
105. Goldstein I. Neurologic impotence. In: Krane RJ, Siroky MVB, Goldstein I eds. Male sexual dysfunction. Boston: Little, Brown and Co. 1983, 193-201.
106. Campese VM, Massary SG. Autonomic nervous system dysfunction and impotence in uremia. Am J Nephrol 1982, 2: 140-3.
107. Brune S, Lucking CH. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex in normal subjects. Clin Autonom Res 1996, 6: 3-15.
108. Diemond WL, Meuleman EJ. Neurological testing in erectile dysfunction. J Androl 1997, 4: 345-50.
109. Derouet H, Ziegler M. Penile sympathetic skin response in erectile dysfunction. Eur Urol 1995, 28: 314-9.
110. Gutrecht JA. Sympathetic skin response. J Clin Neurophysiol 1994, 11: 519-24.
111. Beck R, Fowler CJ. Neurophysiological testing in erectile dysfunction. In: Carson C, Kirby R, Goldstein I eds. Textbook of erectile dysfunction. Oxford: Isis. 1999, 257-66.
112. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 2002, 4: 397-401.
113. Wabrek AJ, Burchell RC. Male sexual dysfunction associated with coronary heart disease. Arch Sex Behav 1980, 9: 69-75.
114. Gundle MJ, Tate S, et al. Psychological outcome after aortocoronary artery surgery. Am J Psychiatry 1980, 137: 1591-4.
115. Ruzbarski V, Michal V. Morphologic changes in the arterial bed of the penis with ageing: relationship to the pathogenesis of impotence. Invest Urol 1977, 15: 194-9.
116. Agarwal A, Jain DC. Male sexual dysfunction after stroke. J Assoc Physicians India 1989, 37: 505-7.
117. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Clin Exp Hypertens 1999, 21: 1009-60.
118. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993, 16: 642-52.
119. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr. before clinical diagnosis. Diabetes Care 1993, 15: 15-9.
120. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837-53.